Advance Publication by-j-stage
|
|
- Peter Lawrence
- 5 years ago
- Views:
Transcription
1 Circ J doi: /circj.CJ LATE BREAKING CLINICAL TRIAL (JCS 2017) Midterm Outcomes With a Self-Expandable Transcatheter Heart Valve in Japanese Patients With Symptomatic Severe Aortic Stenosis Yoshiki Sawa, MD, PhD; Kei Torikai, MD, PhD; Junjiro Kobayashi, MD, PhD; Hiroshi Niinami, MD, PhD; Toru Kuratani, MD, PhD; Koichi Maeda, MD; Hideaki Kanzaki, MD; Nobuyuki Komiyama, MD, PhD; Yutaka Tanaka, MD, PhD; Angie Zhang; Shigeru Saito, MD Background: Transcatheter aortic valve implantation (TAVI) is a viable alternative to surgical aortic valve replacement in high-risk or inoperable patients with aortic stenosis (AS). Here we report the midterm outcomes of high-risk Japanese patients with severe AS who underwent TAVI with a self-expandable TAV. Methods and Results: The CoreValve Japan Trial was a prospective, multicenter trial of the CoreValve System. A group of 55 patients (mean age 82.5±5.5 years, 30.9% male, 100% NYHA class III/IV, STS 8.0±4.2%) were enrolled in the 26-mm/29-mm CoreValve study, and 20 patients (mean age 81.0±6.6 years, 5.0% male, 100% NYHA class III/IV, STS 7.0±3.3%) were enrolled in the 23-mm CoreValve study, which started 1 year later. For the 26-mm/29-mm cohort, the 3-year all-cause mortality rate was 32.6%; major stroke was 15.4%. Mean pressure gradient (MPG), effective orifice area (EOA), and NYHA class showed sustained improvement. Paravalvular regurgitation (PVR) at 3 years was 28.6% (none), 25.7% (trace), 40.0% (mild), 5.7% (moderate), and 0.0% (severe). For the 23-mm cohort, the 2-year all-cause mortality rate was 5.0%; major stroke was 5.0%. MPG, EOA, and NYHA class showed sustained improvement. PVR at 2 years was 16.7% (none), 33.3% (trace), 44.4% (mild), 5.6% (moderate), and 0.0% (severe). Conclusions: TAVI with the CoreValve System was associated with sustained clinical and functional cardiac improvement in high surgical risk Japanese patients with severe AS. (Clinicaltrials.gov Identifiers: NCT and NCT ) Key Words: Aortic valve stenosis; Midterm follow-up; Transcatheter aortic valve implantation Transcatheter aortic valve implantation (TAVI) has been well-studied in the United States, Canada, and Europe, where it has been shown to be an acceptable therapeutic alternative to surgical AV replacement in highrisk or otherwise inoperable patients with severe, symptomatic aortic stenosis (AS). 1 3 We recently reported the early outcomes of TAVI with the 26-mm and 29-mm CoreValve TAV (Medtronic, Minneapolis, MN, USA) in Japanese patients with severe, symptomatic AS who were deemed to be at high risk for surgical AV replacement. 4 The CoreValve is a trileaflet, bioprosthetic, porcine pericardial tissue valve mounted and sutured in a self-expanding nitinol stent frame. The bioprosthesis is housed in a collapsed position for percutaneous delivery via an 18Fr catheter-based technique and then implanted within the diseased AV. Data obtained at 6 months showed the CoreValve System to be safe and effective for the treatment of Japanese patients with severe AS. 4 Here we report the 3-year clinical outcomes and performance of the CoreValve bioprosthesis in the same patient cohort. Additionally, we report the 2-year outcomes of a separate cohort of Japanese patients with severe AS who had a small aortic annulus and received the 23-mm CoreValve bioprosthesis, which became available 1 year after the start of the 26-mm/29-mm CoreValve study. Methods Study Design The CoreValve Japan Trial was a prospective, multicenter, Received February 1, 2017; revised manuscript received March 9, 2017; accepted March 10, 2017; released online March 17, 2017 Time for primary review: 21 days Osaka University Hospital, Osaka (Y.S., K.T., T.K., K.M.); Shonan Kamakura General Hospital, Kamakura (Y.T., S.S.); National Cerebral and Cardiovascular Center, Suita (J.K., H.K.); Saitama Medical University International Medical Center, Saitama (H.N., N.K.), Japan; and Medtronic, Minneapolis, MN (A.Z.), USA This paper was presented at the 81 st Annual Scientific Meeting of the Japanese Circulation Society, Late Breaking Clinical Trials 1-2 (March 17, 2017, Kanazawa, Japan). Mailing address: Yoshiki Sawa, Professor, MD, PhD, Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita , Japan. sawa@surg1.med.osaka-u.ac.jp ISSN All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 SAWA Y et al. single-arm trial to evaluate the efficacy and safety of the 23-, 26-, and 29-mm CoreValve TAV for the treatment of symptomatic, severe AS in Japanese patients who were high-risk surgical AV replacement candidates. The study s design has been previously reported. 4 Briefly, key patient inclusion criteria were severe symptomatic AS with a mean gradient >40 mmhg and an aortic valve area 0.8 cm 2. Primary anatomical exclusion criteria were: a native aortic annulus size <20 mm or >27 mm for the 26-mm/29-mm cohort and <18 mm or >20 mm for the 23-mm cohort; a pre-existing prosthetic heart valve in any position; mixed AV disease with predominant aortic regurgitation (AR); moderate to severe mitral or tricuspid valve regurgitation; an ascending aorta diameter >40 mm for the 26-mm/29-mm cohort and >34 mm for the 23-mm cohort; bicuspid or unicuspid valve; or femoral or iliac arterial diameter <6 mm (unable to accommodate an 18Fr sheath). Native aortic annuli were measured using computed tomography (CT) and transthoracic or transesophageal echocardiography; however, CT was the primary method used. Major-minor aortic annulus diameter and aortic annulus perimeter assessments were performed. Preprocedural CT was mandatory in the CoreValve Japan Studies, and all patients met this study requirement. Antiplatelet and anticoagulation therapies including daily aspirin mg and ticlopidine (according to the manufacturer s instructions for use) were recommended for at least 3 months following the procedure. Continuation beyond 3 months was left to the treating physician s discretion. The primary endpoint for the study was a composite of improvement of at least 1 New York Heart Association (NYHA) class and an effective orifice area (EOA) of >1.2 cm 2 for the 26-mm/29-mm valve cohort or 1.0 cm 2 for the 23-mm valve cohort at 6 months post-procedure in patients who underwent TAVI with the CoreValve via iliofemoral access. The primary endpoint result for the 26-mm/29-mm valve cohort has been previously reported; 4 the primary endpoint for the 23-mm valve cohort is presented in this report. Additionally, for both cohorts, key endpoints analyzed were major adverse cardiovascular and cerebrovascular events (MACCE), NYHA class, echocardiographic valve assessment, valve-related death, adverse events, and quality of life. Except for the primary endpoint for the 23-mm cohort, results are reported for each study arm s cohort in aggregate regardless of the TAVI access approach. Definitions Myocardial infarction (MI), stroke, vascular complications, life-threatening or disabling bleeding events, and paravalvular regurgitation (PVR) were defined using Valve Academic Research Consortium (VARC) I definitions, which were the current VARC definitions in use when this study was conducted. 5 MACCE was defined as a composite rate of all-cause death, MI, all stroke and reintervention. Reintervention was defined as any cardiac surgery or percutaneous catheter intervention (PCI) procedure that repaired, otherwise altered or adjusted, or replaced a previously implanted valve. Valve-related death was defined as any death caused by prosthetic valve dysfunction, valve thrombosis, embolism, bleeding event, or implanted valve endocarditis or related to reintervention on the operated valve. Quality of life was evaluated using the Short Form (SF)-36 health survey. Study Oversight An independent Echocardiographic Core Laboratory (Mayo Clinic Echocardiographic Core Laboratory, Rochester, MN, USA) was responsible for the review and analysis of echocardiographic images. A Clinical Events Committee (CEC), also independent from the study investigators, evaluated all clinical endpoints. The study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki, pharmaceutical affairs law, and good clinical practice. The institutional review board at each center approved the study protocol, and a signed informed consent form was received from all patients. Statistical Analysis Descriptive statistics were used to report baseline demographics and clinical variables. For the 23-mm cohort, the comparator for the primary study objective was conventional therapy, which included medical management and balloon aortic valvuloplasty. Categorical variables are summarized as frequencies and percentages. Continuous variables are summarized as mean ± standard deviation. For NYHA class, echocardiographic assessment of valve performance, and the SF-36, Wilcoxon signed-rank tests were performed to evaluate the median change from baseline at discharge, then 1, 6, 12, and 24 months (23-mm CoreValve cohort), and discharge, and 1, 6, 12, 24, and 36 months (26-mm/29-mm CoreValve cohort) for implanted patients. Kaplan-Meier analyses were performed for safety endpoints. Results Patients Characteristics From October 2011 to October 2012, 55 patients with severe symptomatic AS were enrolled at 4 investigational centers in Japan, of whom 44 underwent attempted TAVI with the 26- or 29-mm CoreValve via the iliofemoral approach, 5 by the subclavian route, and 6 by the direct aortic approach; 38 (70.4%) patients received the 26-mm valve and 16 (29.6%) received the 29-mm valve. For all patients, mean age was 82.5±5.5 years, 30.9% were male, mean Society of Thoracic Surgeons (STS) score was 8.0±4.2%, mean logistic EuroSCORE was 21.5±9.9%, and all patients had NYHA class III (89.1%) or IV (10.9%) symptoms. From July 2012 to August 2013, 20 patients with severe, symptomatic AS and a small aortic annulus were enrolled at the same 4 investigational centers in Japan, of whom 16 underwent attempted TAVI with the 23-mm CoreValve via the iliofemoral approach and 4 by the direct aortic approach. For all patients, mean age was 81.0±6.6 years, 5.0% were male, mean STS score was 7.0±3.3%, mean logistic EuroSCORE was 22.3±10.1%, and all patients had NYHA class III (95.0%) or IV (5.0%) symptoms. Baseline characteristics for both cohorts are summarized in Table 1. Patient disposition for both cohorts is presented in Figure 1. Clinical Outcomes 26-mm/29-mm Cohort Kaplan-Meier rates for adverse events for patients in the 26-mm/29-mm CoreValve cohort are presented in Table 2. The Kaplan-Meier rate for allcause death was 13.0% at 1 year, 18.7% at 2 years, and 32.6% at 3 years (Figure 2). Two deaths were adjudicated
3 Midterm Outcomes for Self-Expandable THV in Japan Table 1. Baseline Patient Characteristics in the CoreValve Japan Trial Characteristic 26/29 mm 23 mm All patients (n=55) All patients (n=20) Age (years) 82.5± ±6.6 Male 17 (30.9) 1 (5.0) NYHA classification II 0 (0.0) 0 (0.0) III 49 (89.1) 19 (95.0) IV 6 (10.9) 1 (5.0) STS score (%) 8.0± ±3.3 <4 7 (12.7) 1 (5.0) (61.8) 16 (80.0) >10 14 (25.5) 3 (15.0) Logistic EuroSCORE (%) 21.5± ±10.1 Diabetes mellitus 19 (34.5) 3 (15.0) Creatinine level >2 mg/dl 0 (0.0) 0 (0.0) History of hypertension 50 (90.9) 16 (80.0) Peripheral vascular disease 18/53 (34.0) 8 (40.0) Prior stroke 15/54 (27.8) 0 (0.0) Prior TIA 3/54 (5.6) 0 (0.0) Cardiac history CAD 27 (49.1) 10 (50.0) Prior CABG 11 (20.0) 3 (15.0) Prior PCI 17 (30.9) 6 (30.0) Prior balloon valvuloplasty 3 (5.5) 1 (5.0) Previous MI 5 (9.1) 1 (5.0) Pre-existing pacemaker 3 (5.5) 0 (0.0) Congestive heart failure 49 (89.1) 16 (80.0) Prior atrial fibrillation/atrial flutter 7/54 (13.0) 5 (25.0) Chronic lung disease/chronic obstructive pulmonary disease 24 (43.6) 14 (70.0) Echocardiographic parameters MPG (mmhg) 57.8± ±18.0 Mean aortic valve area (cm 2 ) 0.6± ±0.1 Moderate or severe AR 3 (5.5) 1 (5.0) Frailty Anemia with transfusion 1 (1.8) 1 (5.0) BMI <21 kg/m 2 16 (29.1) 8 (40.0) Albumin <3.3 g/dl 3/54 (5.6) 1 (5.0) Unplanned weight loss 7 (12.7) 3 (15.0) Fall in past 6 months 2 (3.6) 2 (10.0) 5-m gait speed (s) 8.5±4.2 (n=39) 8.1±4.2 (n=19) 5-m gait speed >6 s 30/39 (76.9) 12/19 (63.2) Grip strength below threshold 50 (90.9) 17 (85.0) Disability Wheelchair bound 16 (29.1) 5 (25.0) Does not live independently 17 (30.9) 8 (40.0) Does not bathe independently 16 (29.1) 8 (40.0) Does not dress independently 3 (5.5) 2 (10.0) Does not toilet independently 4 (7.3) 1 (5.0) Does not transfer independently 10 (18.2) 3 (15.0) Values are mean ± SD or N (percentages) or n/n (percentages). AR, aortic regurgitation; BMI, body mass index; CABG, coronary artery bypass surgery; CAD, coronary artery disease; MI, myocardial infarction; MPG, mean pressure gradient; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack. by the CEC as valve-related. One patient underwent successful implantation of a 26-mm CoreValve bioprosthesis but became unstable after transfer to the intensive care unit and subsequently underwent pericardiocentesis. The next evening emergency surgery revealed a left retroperitoneal hemorrhage from the left external iliac artery, the patient remained unstable and died on postoperative day 2. The other patient died from an intracranial bleed 3 years
4 SAWA Y et al. Figure 1. Patient disposition for the 26-mm/29-mm and 23-mm CoreValve cohorts. Table 2. Kaplan-Meier Rates of Adverse Events to 3 Years for Patients Receiving the 26-mm or 29-mm CoreValve (n=55) Assessment 1 month 6 months 1 year 2 years 3 years MACCE 6 (10.9) 10 (18.4) 13 (23.9) 17 (31.4) 23 (42.7) All-cause death 1 (1.8) 5 (9.2) 7 (13.0) 10 (18.7) 17 (32.6) Cardiovascular death 1 (1.8) 3 (5.5) 3 (5.5) 5 (9.6) 8 (17.2) Stroke 4 (7.4) 5 (9.3) 6 (11.4) 8 (15.7) 10 (21.0) Major stroke 2 (3.7) 2 (3.7) 3 (5.8) 5 (10.1) 7 (15.4) Ischemic 1 (1.9) 1 (1.9) 2 (3.9) 4 (8.3) 5 (10.9) Hemorrhagic 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9) 2 (4.9) Myocardial infarction 2 (3.6) 2 (3.6) 2 (3.6) 2 (3.6) 2 (3.6) Reintervention 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Valve thrombosis* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Major vascular complication 6 (10.9) 6 (10.9) 6 (10.9) 6 (10.9) 6 (10.9) Life-threatening/disabling bleeding 7 (12.8) 8 (14.7) 9 (16.6) 10 (18.7) 11 (21.5) Atrial fibrillation** 3/51 (5.9) 5/47 (10.6) 6/45 (13.3) 4/42 (9.5) 3/36 (8.3) Permanent pacemaker 12 (22.2) 14 (26.3) 14 (26.3) 15 (28.6) 15 (28.6) Data reported as no. of patients (Kaplan-Meier rates as percentages). *Doppler ultrasound echocardiography used for valve thrombosis evaluation. **Atrial fibrillation is reported as incidence [n/n, (percentage)] and not as a Kaplan-Meier rate. MACCE, major adverse cardiovascular and cerebrovascular events. post-procedure. The definition of a valve-related death includes any death caused by prosthetic valve dysfunction, valve thrombosis, embolism, bleeding event, or implanted valve endocarditis or related to reintervention on the operated valve. No patients required reintervention through 3 years follow-up. Two cases of MI occurred within 1 month of the procedure. The first patient had a history of prior coronary artery bypass grafting and PCI. Following valve implantation, a post-tavr balloon valvuloplasty was performed after moderate AR was noted. The patient became hypotensive and coronary angiography revealed absence of flow in the left circumflex coronary artery. Creatinine kinase (CK) and troponin levels the following day confirmed the MI. On the 2nd postoperative day PCI of the affected vessel was performed. The second patient also had a history of prior PCI. During the TAVR procedure cardiac perforation and tamponade occurred after pre-tavr balloon valvuloplasty. Transient myocardial damage caused by hypotension was suspected, which was treated with percutaneous cardiopulmonary support. CK and CK MB elevation was noted on the 1st postoperative day, but no ischemic-event related ECGs were provided. The CEC noted that the periprocedural MI was related to the CoreValve device. There were no subsequent cases of MI reported through 3 years; thus, the rate for MI remained 3.6%. The rate of major stroke was 5.8% at 1 year, 10.1% at 2 years, and 15.4% at 3 years; however, only 3 of the 7 major strokes that occurred over the 3-year follow-up were adjudicated by the CEC as related to the device or procedure. The CEC adjudicated stroke events by a few criteria, one of which was proximity to the implant procedure. For 2 of the patients, the stroke event occurred within 30 days of the implant procedure, so was adjudicated as related to the device or procedure. In the 3rd patient, the stroke
5 Midterm Outcomes for Self-Expandable THV in Japan Figure 2. Kaplan-Meier estimates of all-cause mortality to the longest follow-up for each cohort. Figure 4. Paravalvular regurgitation over time for the (A) 26-mm/29-mm CoreValve cohort and (B) 23-mm CoreValve cohort. Note the follow-up time points vary for each panel based on completed follow-up for each cohort. Figure 3. New York Heart Association (NYHA) class over time for the (A) 26-mm/29-mm CoreValve cohort and (B) 23-mm CoreValve cohort. Note the follow-up time points vary for each panel based on completed follow-up for each cohort. occurred 605 days after the implant procedure, but the patient also had endocarditis, attributed to the valve, and the CEC considered the stroke likely device-related because of the valve-associated endocarditis. There were no signs of valve deterioration or thrombus observed during followup. The rate of MACCE was 23.9%, 31.4%, and 42.7% at 1, 2, and 3 years, respectively. Using VARC I definitions, the rate of life-threatening or disabling bleeding was 16.6% at 1 year, 18.7% at 2 years, and 21.5% at 3 years. The rate of major vascular complications was 10.9% at 1 month and remained unchanged throughout the remainder of the follow-up period. Permanent pacemaker implantation was required in 14 patients in the 1st year of follow-up, with 1 additional patient needing a permanent pacemaker in the 2nd year, and none in the 3rd year. The pacemaker implantation rates are shown in Table 2. For patients with follow-up data, improvement in NYHA classification was sustained over 3 years (Figure 3A). As shown in Figure 4A, the rate of PVR remained stable over time, with 2 (5.7%) patients having moderate and no patients having severe PVR at 3 years. Improvements in mean pressure gradient (MPG) and EOA were also stable over time (Figure 5A). Quality of life measurements showed improvement in the SF-36 physical component summary score of 10.8 points (P=0.008) at 1 year, 9.3 points (P=0.002) at 2 years, and 4.8 points (P=0.151) at 3 years. However, the SF-36 mental component summary score showed only slight improvement, increasing by 2.8 points (P=0.016) at 1 year, 2.9 points (P=0.220) at 2 years, and 1.5 points (P=0.240) at 3 years. 23-mm Cohort A total of 16 iliofemoral patients were
6 SAWA Y et al. Figure 5. Mean pressure gradient and effective orifice area over time for the (A) 26-mm/29-mm CoreValve cohort and (B) 23-mm CoreValve cohort. Note the follow-up time points vary for each panel based on completed follow-up for each cohort. enrolled in the 23 mm study. Analysis of the primary endpoint showed that iliofemoral patients achieved a composite NYHA and EOA success rate of 87.5% (14/16). The lower bound of the 2-sided 95% confidence interval was 61.7%, indicating the performance of the 23-mm CoreValve was superior to conventional therapy outcomes of 50% improvement and the primary study objective was met (P=0.002). Kaplan-Meier rates for adverse events for patients in the 23-mm CoreValve cohort (n=20) are presented in Table 3. The Kaplan-Meier rate for all-cause death was 0.0% at 1 year, and 5.0% at 2 years (Figure 2). No cases of MI, reintervention, or valve-related death occurred through 2 years. The rate of major stroke was 0.0% at 1 year and 5.0% at 2 years. The rate of MACCE was 0.0% at 30 days, 5.0% at 6 months and 1 year, and 10.0% at 2 years. Using VARC I definitions, the rate of life-threatening or disabling bleeding was 10.0% at 30 days, 15% at 1 year, and remained unchanged at 2 years. The rate of major vascular complications was 15% at 30 days and remained unchanged throughout the remainder of the follow-up period. Permanent pacemaker implantation was required in 4 patients in the 1st month of follow-up, with an additional patient needing a permanent pacemaker in the 1st year, and none in the 2nd year. The percentages of patients with a pacemaker are shown in Table 3. At baseline, all patients were in NYHA class III or IV; all patients followed to 6 months were in NYHA class I or II and remained so through 2 years (Figure 3B). PVR showed sustained improvement over time, with only one (5.6%) patient having moderate and no patients having severe PVR at 2 years (Figure 4B). Improvements in MPG and EOA also remained stable over time (Figure 5B). There was no statistically significant improvement in the SF-36 physical or mental component summary scores through 2 years of follow-up. Discussion This study reports the midterm experience with the Table 3. Kaplan-Meier Rates of Adverse Events to 2 Years for Patients Receiving the 23-mm CoreValve (n=20) Assessment 1 month 6 months 1 year 2 years MACCE 0 (0.0) 1 (5.0) 1 (5.0) 2 (10.0) All-cause death 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) Cardiovascular death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Stroke 0 (0.0) 1 (5.0) 1 (5.0) 1 (5.0) Major stroke 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) Ischemic 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) Hemorrhagic 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Myocardial infarction 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Reintervention 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Valve thrombosis* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Major vascular complication 3 (15.0) 3 (15.0) 3 (15.0) 3 (15.0) Life-threatening/disabling bleeding 2 (10.0) 3 (15.0) 3 (15.0) 3 (15.0) Atrial fibrillation** 2/20 (10.0) 1/20 (5.0) 2/20 (10.0) 1/18 (5.6) Permanent pacemaker 4 (20.0) 4 (20.0) 5 (25.0) 5 (25.0) Data reported as no. of patients (Kaplan-Meier rates as percentages). *Doppler ultrasound echo used for valve thrombosis evaluation. **Atrial fibrillation is reported as incidence [n/n, (percentage)] and not as a Kaplan-Meier rate. MACCE, major adverse cardiovascular and cerebrovascular events.
7 Midterm Outcomes for Self-Expandable THV in Japan CoreValve 23-, 26-, and 29-mm bioprostheses in the Japanese population. Overall, the results demonstrated that TAVI with the CoreValve System was associated with sustained clinical and functional cardiac improvement in high-risk Japanese patients with severe AS. In the 26-mm/29-mm cohort, MACCE occurred in 23 patients through 3 years of follow-up; 17 patients died, of whom 8 died from cardiac causes; 2 deaths were related to the TAV. The 3-year mortality rate was 32.6%. Although high, this mortality rate is not unexpected given the severity of AS, advanced age, and frailty of this patient cohort. The 3-year mortality rate is also similar to that reported by other larger studies evaluating the CoreValve in high-risk AS patients. 6,7 Stroke remains an important problem with any AV intervention, be it surgical or catheter-based. 8 In the 26-mm/29-mm CoreValve cohort, 7 patients experienced a major stroke through 3 years of follow-up, resulting in a Kaplan-Meier rate for major stroke of 15.4%, which is higher than that reported by larger, long-term studies of the CoreValve device; 8,9 however, the small sample size (n=55) in the present study had a larger effect on calculated event rates compared with other much larger CoreValve studies. Additionally, in review of the 7 major stroke events, only 3 were adjudicated by the CEC as being related to the CoreValve bioprosthesis or procedure. Of these, 1 was a subarachnoid hemorrhage, which occurred within 30 days of the procedure, and 2 were ischemic strokes, one of which occurred within 30 days of the procedure, and 1 which occurred between the 1- and 2-year follow-up visits. Cardiac conduction disorders requiring permanent pacemaker implantation are one of the most common complications seen after TAVI. In the present study, 15 patients who received either the 26-mm or 29-mm device required a permanent pacemaker through 3 years, resulting in a Kaplan-Meier rate of 28.6%. However, pacemaker implantation was required in the majority of cases (12 patients) within 30 days of the TAVI procedure. The incidence of permanent pacemaker implantation in the present study is similar to that reported for this TAV device, and several recent studies have found no adverse effect of permanent pacemaker implantation after TAVI with this device on stroke or survival. 10,11 Echocardiography core laboratory data continued to demonstrate the durability of the CoreValve bioprosthesis. No significant changes in the hemodynamic status of the implanted 26-mm/29-mm bioprostheses were seen, and the MPG and EOA remained stable from discharge to 3 years. There was no evidence of valve thrombosis during the follow-up period. PVR remained stable over time, with only 2 (5.7%) patients having moderate PVR and no patients having severe PVR at 3-year follow-up. In the 26-mm/29-mm cohort, NYHA functional classification showed sustained improvement over time, with all surviving patients classified as either NYHA class I or II at 3 years compared with class III or IV at baseline. There was also statistically significant improvement in the SF-36 physical component summary score through 2 years; however, this diminished by the 3rd year. The SF-36 mental component summary score showed only modest improvement, achieving statistical significance only at 1-year followup. Although the reason for the more limited improvement in the mental component summary results is unclear, other studies of TAVI in high-risk AS patients have documented similarly modest benefits in psychological measures. 12 We also evaluated the 2-year outcomes of a separate cohort of Japanese patients with severe AS and a small aortic annulus who received the 23-mm CoreValve bioprosthesis. Overall, this valve performed well in this patient group, and the primary endpoint was met. There were 3 cases of MACCE occurred in 2 patients: 1 patient died from non-cardiac causes, and 1 patient had 2 stroke events over 2 years; 5 patients required a permanent pacemaker through 2 years, resulting in a Kaplan-Meier rate of 25.0%. No significant changes post-procedure in the hemodynamic status of the implanted 23-mm bioprosthesis were seen and PVR was stable over time, with only one patient having moderate and no patients having severe PVR at 2 years. NYHA functional classification also showed sustained improvement over time. We did not observe significant improvement in the SF-36 physical or mental component summary scores at any follow-up time point, which may have been limited by the small study cohort. Study Limitations The primary limitation of both these studies was the small sample size, which also resulted in each event having a larger effect on event rates than is seen in larger trials. Conclusions This study demonstrated that TAVI with the self-expanding CoreValve was associated with sustained, multi-year clinical and functional cardiac improvement in high-risk surgical Japanese patients with severe, symptomatic AS. Disclosures Angie Zhang is an employee and shareholder of Medtronic, Plc. Acknowledgments The authors thank Janice Hoettels, PA, MBA and Jane Moore, MS, ELS for their assistance in the preparation of this manuscript. Both are employed by Medtronic. Funding This work was supported by Medtronic Japan Co. Ltd. References 1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: e521 e Webb J, Rodés-Cabau J, Fremes S, Pibarot P, Ruel M, Ibrahim R, et al. Transcatheter aortic valve implantation: A Canadian Cardiovascular Society position statement. Can J Cardiol 2012; 28: Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: Sawa Y, Saito S, Kobayashi J, Niinami H, Kuratani T, Maeda K, et al. First clinical trial of a self-expandable transcatheter heart valve in Japan in patients with symptomatic severe aortic stenosis. Circ J 2014; 78: Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: A consensus report of the Valve Academic Research Consortium. Eur Heart J 2011; 32: Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM,
8 SAWA Y et al. Yakubov SJ, et al. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 67: Ussia GP, Barbanti M, Petronio AS, Tarantini G, Ettori F, Colombo A, et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J 2012; 33: Gleason TG, Schindler JT, Adams DH, Reardon MJ, Kleiman NS, Caplan LR, et al. The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. J Thorac Cardiovasc Surg 2016; 151: Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb M, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: Testa L, Latib A, De Marco F, De Carlo M, Agnifili M, Latini RA, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve Revalving System. Circulation 2013; 127: Ledwoch J, Franke J, Gerckens U, Kuck KH, Linke A, Nickening G, et al. Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: Analysis from the German transcatheter aortic valve interventions registry. Catheter Cardiovasc Interv 2013; 82: E569 E Kim CA, Rasania SP, Afilalo J, Popma JJ, Lipsitz LA, Kim DH. Functional status and quality of life after transcatheter aortic valve replacement: A systematic review. Ann Intern Med 2014; 160:
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTrend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience
Cardiol Ther (2018) 7:191 196 https://doi.org/10.1007/s40119-018-0115-0 BRIEF REPORT Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Anthony A. Bavry.
More informationTranscatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationTranscatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for
Transcatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for Surgery: One-Year Results from the Evolut R US Pivotal Study
More informationFor the SURTAVI Investigators
Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter
More informationOutcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationNouvelles indications/ Nouvelles valves
Nouvelles indications/ Nouvelles valves Sadra Lotus Valve system Boston Scientific A. Tirouvanziam Institut Thorax Nantes SH-31314-AC Sept 2012 Slide 1 of 53 SH-31314-AC Sept 2012 Slide 2 of 53 Building
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationTAVI in Korea, How to Avoid Conduction
TAVI in Korea, How to Avoid Conduction Disturbance after CoreValve Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul,
More informationIs TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationVariability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience
DOI 10.1007/s40119-015-0050-2 BRIEF REPORT Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience Jeffrey E. Rossi. Andrew Noll. Brian Bergmark. James M. McCabe.
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: Original Effective Date: MM.06.019 10/01/2012 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/27/2018
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationEarly Outcomes in Japanese Dialysis Patients Treated With Transcatheter Aortic Valve Implantation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Valvular Heart Disease Early Outcomes in Japanese Dialysis Patients Treated With Transcatheter
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: Original Effective Date: MM.06.019 10/01/2012 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/26/2017
More informationDr.ssa Loredana Iannetta. Centro Cardiologico Monzino
Dr.ssa Loredana Iannetta Centro Cardiologico Monzino Bicuspid aortic valve BAV is the most common congenital cardiac anomaly. Estimated incidence is 2% in general population. 4:1 male predominance. Frequency
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationTranscatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee
Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More information3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong
3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease
More informationIncidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation
ESC Congress 2010 28 Aug 2010-01 Sep 2010 Stockholm - Sweden Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation Gian Paolo Ussia, MD Director of Interventional
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More informationTranscatheter Heart Valve Procedures
Medical Coverage Policy Transcatheter Heart Valve Procedures Table of Contents Coverage Policy... 1 Overview... 2 General Background... 2 Coding/Billing Information... 27 References... 29 Effective Date...11/15/2017
More informationTranscatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.
Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationRole of Embolic Protection during TAVR
Role of Embolic Protection during TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Disclosure Co PI for Sentinel Trial
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationSuccessful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationCase Presentations TAVR: The Good Bad and The Ugly
Case Presentations TAVR: The Good Bad and The Ugly Vincent J. Pompili, MD, FACC, FSCAI Professor of Internal Medicine Director of Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories
More informationInterventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationTRANSCATHETER HEART VALVE PROCEDURES
UnitedHealthcare Commercial Medical Policy TRANSCATHETER HEART VALVE PROCEDURES Policy Number: 2018T0557N Effective Date: February 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs
More informationTRANSCATHETER HEART VALVE PROCEDURES
UnitedHealthcare Commercial Medical Policy TRANSCATHETER HEART VALVE PROCEDURES Policy Number: 2017T0557M Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs
More information30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators
30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationstenosis (AS) at our center between June 2007 and December 2010, with last follow-up contact in 2016.
Featured Article Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves Giuseppe Tarantini
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationTranscatheter aortic valve implantation for aortic stenosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs when the aortic valve
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationInterventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586
Transcatheter aortic valve implantation for aortic stenosis Interventional procedures guidance Published: 26 July 17 nice.org.uk/guidance/ipg586 Your responsibility This guidance represents the view of
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationBernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium
Medium Term Survival and Functional Status in Patients with Severe Aortic Stenosis Treated by Transcatheter Aortic Valvular Implantation in the PARTNER EU Trial Bernard De Bruyne, MD, PhD Cardiovascular
More informationThe advent of transcatheter aortic valve implantation. Vascular Complications Among Patients. cover story
Vascular Complications Among Patients Undergoing TAVR Contemporary concepts facing operators in this challenging patient population. By Stefan Stortecky, MD, and Peter Wenaweser, MD The advent of transcatheter
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationTranscatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) QEH Registry A Multidisciplinary Team Approach Michael KY Lee 1, LK Chan 1, KC Chan 1, KT Chan 1, SF Chui 1, HS Ma 1, CY Wong 1, CS Chiang 1, P Li 1, CB Lam
More information